Gary McCord

Gary McCord brings nearly 30 years of sales, marketing, and management experience in the medical device industry. Prior to joining Venclose in 2017, he was part of the executive team at TriReme Medical, a California-based subsidiary of QT Vascular, which develops and manufactures therapies for complex vascular disease. Prior, he was Vice President of Business Development at Sapheon (acquired by Covidien, now part of Medtronic), a developer of closure systems for treatment of venous reflux disease. Before joining Sapheon, Mr. McCord was Director of Coronary Franchise at Cardiovascular Systems, Inc. Earlier in his career, Mr. McCord held various sales and management positions with Fox Hollow Technologies, Pilot Cardiovascular Systems, Heart Technologies, Ventritex, Interventional Technologies, and X-Technologies—all privately held, entrepreneurial cardiology enterprises later acquired by companies such as C.R. Bard, Boston Scientific, Guidant, and St. Jude Medical. Mr. McCord holds a Bachelor of Arts in Communications degree from the University of Missouri, Columbia.